MCID: NRC002
MIFTS: 59

Narcolepsy

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 76 53 25 54 37 55 44 15 63 73
Narcolepsy-Cataplexy Syndrome 53 73
Narcoleptic Syndrome 53 25
Gelineau Syndrome 53 25
Paroxysmal Sleep 12 53
Narcolepsy, Without Cataplexy 12
Gelineau's Syndrome 53

Classifications:



External Ids:

Disease Ontology 12 DOID:8986
ICD10 33 G47.41 G47.419
ICD9CM 35 347.0
MeSH 44 D009290
NCIt 50 C84489
SNOMED-CT 68 60380001
KEGG 37 H01293

Summaries for Narcolepsy

NINDS : 54 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience overpowering bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis. The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including hemiplegia, excessive daytime somnolence and sleep disturbances. An important gene associated with Narcolepsy is PICSAR (P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA), and among its related pathways/superpathways are Th17 cell differentiation and Human T-cell leukemia virus 1 infection. The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference : 25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases : 53 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial. There is no cure, but some symptoms can be managed with medicines and lifestyle changes.

PubMed Health : 63 About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness.Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity.Narcolepsy also can cause:

Wikipedia : 76 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 narcolepsy 1 34.5 HCRT HLA-DQB1 HLA-DRB1 MOG P2RY11
2 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 34.5 DNMT1 HCRT
3 narcolepsy 2 34.1 HCRT HLA-DQB1 HLA-DRB1 NRCLP2
4 idiopathic hypersomnia 33.1 HCRT HLA-DQB1
5 hypersomnia 32.8 HCRT HLA-DQB1 HLA-DRB1
6 sleep disorder 32.4 HCRT HCRTR1 HCRTR2 LEP MOG
7 sleep apnea 31.0 HCRT LEP TNF
8 apnea, obstructive sleep 30.6 HCRT LEP TNF
9 autoimmune disease 30.5 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG TNF
10 neuromyelitis optica 30.5 HCRT HLA-DRB1 MOG
11 recurrent hypersomnia 30.4 HCRT HLA-DQB1
12 diabetes mellitus 30.1 HLA-DQA1 HLA-DQB1 HLA-DRB1 LEP TNF
13 acute disseminated encephalomyelitis 30.0 HCRT HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
14 celiac disease 1 29.7 HLA-DQA1 HLA-DQB1 TNF
15 narcolepsy 7 12.5
16 narcolepsy 4 12.1
17 narcolepsy 5 12.1
18 narcolepsy 3 12.1
19 narcolepsy 6 12.1
20 disseminated sclerosis with narcolepsy 12.0
21 influenza 10.6
22 limbic encephalitis with lgi1 antibodies 10.4 HLA-DQB1 HLA-DRB1
23 achalasia, familial esophageal 10.4 HLA-DQA1 HLA-DQB1
24 autoimmune disease of peripheral nervous system 10.4 HCRT MOG TNF
25 autoimmune polyglandular syndrome type 3 10.4 HLA-DQB1 HLA-DRB1
26 pediatric multiple sclerosis 10.3 HLA-DQB1 HLA-DRB1 MOG
27 chronic beryllium disease 10.3 HLA-DQB1 HLA-DRB1 TNF
28 microscopic colitis 10.3 HLA-DQB1 HLA-DRB1 TNF
29 endometritis 10.3 HLA-DQA1 HLA-DQB1 TNF
30 guillain-barre syndrome 10.3 HCRT HLA-DQB1 TNF
31 glaucomatocyclitic crisis 10.3 HLA-DQB1 HLA-DRB1 TNF
32 geographic tongue 10.3 HLA-DQB1 HLA-DRB1 TNF
33 panuveitis 10.3 HLA-DQB1 HLA-DRB1 TNF
34 idiopathic bronchiectasis 10.3 HLA-DQA1 HLA-DQB1 HLA-DRB1
35 rohhad 10.3 HCRT HCRTR1 HCRTR2
36 sympathetic ophthalmia 10.3 HLA-DQA1 HLA-DRB1 TNF
37 optic neuritis 10.3 HLA-DRB1 MOG TNF
38 metal allergy 10.3 HLA-DQB1 HLA-DRB1
39 primary progressive multiple sclerosis 10.3 HLA-DRB1 MOG TNF
40 focal epithelial hyperplasia 10.3 HLA-DQA1 HLA-DQB1 HLA-DRB1
41 lichen planopilaris 10.3 HLA-DQB1 HLA-DRB1
42 autoimmune disease of central nervous system 10.3 HLA-DRB1 MOG TNF
43 rubella 10.3 HLA-DQB1 HLA-DRB1 MOG TNF
44 rheumatic fever 10.3 HLA-DQA1 HLA-DRB1 TNF
45 nervous system disease 10.3 ATXN3 MOG TNF
46 autoimmune disease of the nervous system 10.3 HLA-DRB1 MOG TNF
47 type ii mixed cryoglobulinemia 10.3 HLA-DQB1 HLA-DRB1
48 microscopic polyangiitis 10.3 HLA-DRB1 TNF
49 rheumatic heart disease 10.3 HLA-DQA1 HLA-DRB1 TNF
50 toxoplasmosis 10.3 HLA-DQA1 HLA-DQB1 TNF

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

UMLS symptoms related to Narcolepsy:


hemiplegia, excessive daytime somnolence, sleep disturbances, snoring, sleeplessness, sluggishness

Drugs & Therapeutics for Narcolepsy

PubMedHealth treatment related to Narcolepsy: 63

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are.Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment.

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112111-43-0
3
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Sodium oxybate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 502-85-2 5360545
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Rasagiline Approved Phase 4 136236-51-6 3052776
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antiparkinson Agents Phase 4,Not Applicable
14 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Pharmaceutical Solutions Phase 4,Phase 3,Early Phase 1
21 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Psychotropic Drugs Phase 4,Not Applicable
24 Anti-Anxiety Agents Phase 4,Not Applicable
25 calcium channel blockers Phase 4
26 Excitatory Amino Acids Phase 4
27 Calcium, Dietary Phase 4,Phase 1,Phase 2
28 Excitatory Amino Acid Antagonists Phase 4
29 Tranquilizing Agents Phase 4,Not Applicable
30 Anticonvulsants Phase 4
31 Antimanic Agents Phase 4
32 Sympathomimetics Phase 4,Phase 2,Phase 1
33 Autonomic Agents Phase 4,Phase 2,Phase 1
34 Protective Agents Phase 4,Phase 1,Phase 2
35 Cardiotonic Agents Phase 4
36 Interferon-alpha Phase 4
37 interferons Phase 4
38 Monoamine Oxidase Inhibitors Phase 4
39 Dopamine agonists Phase 4
40 Antioxidants Phase 4
41 Neuroprotective Agents Phase 4
42
Morphine Approved, Investigational Phase 3 57-27-2 5288826
43
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
44
Methylphenidate Approved, Investigational Phase 2, Phase 3,Not Applicable 113-45-1 4158
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
46
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
47 Analgesics, Opioid Phase 3
48 Narcotics Phase 3
49 Histamine H3 Antagonists Phase 3,Phase 2
50
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
2 Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS Completed NCT00118378 Phase 4 Modafinil;Placebo
3 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
4 Pain Expectations in Subjects With Osteoarthritis Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
5 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
6 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
7 Xyrem and Brain Dopamine in Narcolepsy Recruiting NCT02637076 Phase 4 Xyrem
8 A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Not yet recruiting NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
9 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4 modafinil
10 Armodafinil for Patients Starting Hepatitis C Virus Treatment Terminated NCT01470651 Phase 4 Armodafinil;Sugar Pill
11 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4 Rasagiline;Pramipexole
12 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
13 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
14 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
15 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
16 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
17 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
18 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
19 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
20 Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Completed NCT01399606 Phase 3 BF2.649
21 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
22 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
23 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
24 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
25 Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients Completed NCT00049803 Phase 3 sodium oxybate
26 Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
27 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
28 Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
29 Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Completed NCT01789398 Phase 3 BF2.649
30 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Completed NCT01800045 Phase 3 Pitolisant;Placebo
31 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3 Methylphenidate;Placebo
32 Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3 Nuvigil;Placebo
33 Modafinil in Cancer Related Fatigue Completed NCT01440621 Phase 3 Modafinil;Pyridoxine
34 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
35 Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Recruiting NCT02720744 Phase 3 Sodium Oxybate;Placebo
36 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT02221869 Phase 3 Xyrem
37 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT03030599 Phase 3 JZP-258
38 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
39 A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Completed NCT00424931 Phase 2 JNJ-17216498;JNJ-17216498;Modafinil
40 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
41 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
42 A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
43 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
44 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
45 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2 Flumazenil
46 Methylphenidate and Parkinson's Disease Completed NCT00359723 Phase 2 methylphenidate
47 Sodium Oxybate in Schizophrenia With Insomnia Completed NCT00594256 Phase 2 Sodium Oxybate
48 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
49 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
50 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence Completed NCT00469508 Phase 2 Modafinil;Placebo

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

41
Brain, T Cells, Testes, Eye, Heart, Amygdala, Testis

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 1216)
# Title Authors Year
1
Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: A 5-year follow-up study. ( 29845680 )
2018
2
An overview of hypocretin based therapy in narcolepsy. ( 29623725 )
2018
3
Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report. ( 29942729 )
2018
4
Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. ( 29195824 )
2018
5
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States. ( 29910845 )
2018
6
Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy. ( 29351827 )
2018
7
Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. ( 29784823 )
2018
8
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
9
The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. ( 29198301 )
2018
10
Modafinil Reduces Parasympathetic Activity but Does Not Influence Autonomic Reactivity to Orthostatic Load in Narcolepsy Type 1. ( 29901476 )
2018
11
Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. ( 29449194 )
2018
12
An Epigenome-wide Association Study of DNA Methylation and An Integrated Genetic and Epigenetic Approach for Narcolepsy. ( 29425374 )
2018
13
Anesthetic Management of Narcolepsy Patients During Surgery: A Systematic Review. ( 29257771 )
2018
14
Impact of acute administration of sodium oxybate on heart rate variability in children with type 1 narcolepsy. ( 29880141 )
2018
15
Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy. ( 29771387 )
2018
16
Cyclic hypersomnolence with symptoms of narcolepsy with cataplexy: An unusual presentation of probable immune-mediated encephalitis. ( 29736425 )
2018
17
Remitting Narcolepsy? Longitudinal Observations in a Hypocretin-deficient Cohort. ( 29868885 )
2018
18
Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. ( 29609710 )
2018
19
Narcolepsy Associated with Pandemrix Vaccine. ( 29855798 )
2018
20
Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. ( 29909138 )
2018
21
Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. ( 29950444 )
2018
22
Drugs Used in Narcolepsy and Other Hypersomnias. ( 29759269 )
2018
23
Narcolepsy, brain imaging, and cognition: Understanding the connections. ( 29686129 )
2018
24
Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. ( 29796199 )
2018
25
Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. ( 29321233 )
2018
26
Chronic pain in narcolepsy type 1 and type 2 - an underestimated reality. ( 29923259 )
2018
27
The Association of Schizophrenia and Narcolepsy in Adolescents. ( 29622485 )
2018
28
Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review. ( 29974206 )
2018
29
Childhood narcolepsy and autism spectrum disorders: four case reports. ( 30216768 )
2018
30
A false alarm of narcolepsy: obstructive sleep apnea masquerading as narcolepsy and depression. ( 30523556 )
2018
31
Type 1 narcolepsy in anti-Hu antibodies mediated encephalitis: a case report. ( 30212757 )
2018
32
The Comorbidity of Focal Epilepsy and Narcolepsy Type 1 - Two Case Reports. ( 30183203 )
2018
33
Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. ( 30174215 )
2018
34
Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment. ( 30122647 )
2018
35
Time for a standardized clinical assessment for narcolepsy with obstructive sleep apnea. ( 28623528 )
2018
36
The clinical spectrum of childhood narcolepsy. ( 28666745 )
2018
37
Pediatric Narcolepsy: A Brief Report. ( 28969429 )
2018
38
The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. ( 29019051 )
2018
39
Psychosis in a 22-Year-Old Woman With Narcolepsy After Restarting Sodium Oxybate. ( 29108652 )
2018
40
A Case of Narcolepsy Type 2 and Postural Tachycardia Syndrome Secondary to Lesions of the Thalamus and Amygdala. ( 29458703 )
2018
41
Narcolepsy and Psychiatric Disorders: Comorbidities or Shared Pathophysiology? ( 29462876 )
2018
42
Comorbidities in a community sample of narcolepsy. ( 29482805 )
2018
43
Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. ( 29504180 )
2018
44
Sodium Oxybate Treatment in Pediatric Type 1 Narcolepsy. ( 29512449 )
2018
45
In-field assessment of sodium oxybate effect in pediatric type 1 narcolepsy: an actigraphic study. ( 29522206 )
2018
46
The inappropriate occurrence of rapid eye movement sleep in narcolepsy is not due to a defect in homeostatic regulation of rapid eye movement sleep. ( 29522212 )
2018
47
Flow cytometry analysis of T-cell subsets in cerebrospinal fluid of narcolepsy type 1 patients with long-lasting disease. ( 29530370 )
2018
48
A comparative study of methods for automatic detection of rapid eye movement abnormal muscular activity in narcolepsy. ( 29530376 )
2018
49
Neuroimaging correlates of narcolepsy with cataplexy: A systematic review. ( 29580887 )
2018
50
Neurocognition, sleep, and PET findings in type 2 vs type 1 narcolepsy. ( 29602910 )
2018

Variations for Narcolepsy

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.78 ATXN3 HCRT HCRTR1 HCRTR2
2 neuropeptide signaling pathway GO:0007218 9.7 HCRT HCRTR1 HCRTR2
3 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.67 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.58 HCRT HCRTR2 P2RY11
6 leukocyte tethering or rolling GO:0050901 9.54 LEP TNF
7 negative regulation of glucose import GO:0046325 9.51 LEP TNF
8 antigen processing and presentation GO:0019882 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
9 negative regulation of lipid storage GO:0010888 9.46 LEP TNF
10 T cell receptor signaling pathway GO:0050852 9.46 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.26 HLA-DQB1 HLA-DRB1
13 feeding behavior GO:0007631 9.13 HCRT HCRTR1 HCRTR2
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 orexin receptor activity GO:0016499 8.96 HCRTR1 HCRTR2
3 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....